Medtronic (MDT) Competitors

Intuitive Surgical has a net margin of 28.45% compared to Medtronic's net margin of 13.93%. Intuitive Surgical's return on equity of 16.91% beat Medtronic's return on equity.

Medtronic currently has a consensus price target of $103.92, indicating a potential upside of 12.45%. Intuitive Surgical has a consensus price target of $508.68, indicating a potential upside of 44.86%. Given Intuitive Surgical's higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than Medtronic.

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

In the previous week, Medtronic had 19 more articles in the media than Intuitive Surgical. MarketBeat recorded 49 mentions for Medtronic and 30 mentions for Intuitive Surgical. Intuitive Surgical's average media sentiment score of 1.09 beat Medtronic's score of 0.83 indicating that Intuitive Surgical is being referred to more favorably in the news media.

82.1% of Medtronic shares are owned by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are owned by institutional investors. 0.3% of Medtronic shares are owned by insiders. Comparatively, 0.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

Abbott Laboratories has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Medtronic has a net margin of 13.93% compared to Abbott Laboratories' net margin of 11.65%. Abbott Laboratories' return on equity of 17.69% beat Medtronic's return on equity.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.1%. Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.4%. Medtronic pays out 70.9% of its earnings in the form of a dividend. Abbott Laboratories pays out 81.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medtronic has increased its dividend for 49 consecutive years and Abbott Laboratories has increased its dividend for 54 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and lower payout ratio.

82.1% of Medtronic shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

In the previous week, Abbott Laboratories had 22 more articles in the media than Medtronic. MarketBeat recorded 71 mentions for Abbott Laboratories and 49 mentions for Medtronic. Abbott Laboratories' average media sentiment score of 1.47 beat Medtronic's score of 0.83 indicating that Abbott Laboratories is being referred to more favorably in the news media.

Medtronic presently has a consensus target price of $103.92, suggesting a potential upside of 12.45%. Abbott Laboratories has a consensus target price of $119.50, suggesting a potential upside of 13.37%. Given Abbott Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Abbott Laboratories is more favorable than Medtronic.

Medtronic has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Boston Scientific has a net margin of 17.50% compared to Medtronic's net margin of 13.93%. Boston Scientific's return on equity of 19.28% beat Medtronic's return on equity.

Medtronic currently has a consensus price target of $103.92, indicating a potential upside of 12.45%. Boston Scientific has a consensus price target of $71.46, indicating a potential upside of 57.79%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts clearly believe Boston Scientific is more favorable than Medtronic.

In the previous week, Medtronic had 13 more articles in the media than Boston Scientific. MarketBeat recorded 49 mentions for Medtronic and 36 mentions for Boston Scientific. Medtronic's average media sentiment score of 0.83 beat Boston Scientific's score of 0.51 indicating that Medtronic is being referred to more favorably in the media.

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

82.1% of Medtronic shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 0.3% of Medtronic shares are owned by company insiders. Comparatively, 0.3% of Boston Scientific shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

82.1% of Medtronic shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Johnson & Johnson has a net margin of 21.48% compared to Medtronic's net margin of 13.93%. Johnson & Johnson's return on equity of 32.42% beat Medtronic's return on equity.

In the previous week, Johnson & Johnson had 56 more articles in the media than Medtronic. MarketBeat recorded 105 mentions for Johnson & Johnson and 49 mentions for Medtronic. Johnson & Johnson's average media sentiment score of 1.19 beat Medtronic's score of 0.83 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.1%. Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.0%. Medtronic pays out 70.9% of its earnings in the form of a dividend. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has increased its dividend for 49 consecutive years and Johnson & Johnson has increased its dividend for 64 consecutive years.

Medtronic has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Johnson & Johnson has higher revenue and earnings than Medtronic. Medtronic is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Medtronic presently has a consensus target price of $103.92, indicating a potential upside of 12.45%. Johnson & Johnson has a consensus target price of $272.83, indicating a potential upside of 1.72%. Given Medtronic's higher probable upside, equities research analysts plainly believe Medtronic is more favorable than Johnson & Johnson.